Updates are available Correction dated 2017-06-28
Click to view Correction: https://doi.org/10.1007/s00439-017-1828-1
-
Authors
Zhang, Jing http://orcid.org/0000-0002-6456-7490
Gambin, Tomasz
Yuan, Bo
Szafranski, Przemyslaw
Rosenfeld, Jill A.
Balwi, Mohammed Al
Alswaid, Abdulrahman
Al-Gazali, Lihadh
Shamsi, Aisha M. Al
Komara, Makanko
Ali, Bassam R.
Roeder, Elizabeth
McAuley, Laura
Roy, Daniel S.
Manchester, David K.
Magoulas, Pilar
King, Lauren E.
Hannig, Vickie
Bonneau, Dominique
Denommé-Pichon, Anne-Sophie
Charif, Majida
Besnard, Thomas
Bézieau, Stéphane
Cogné, Benjamin
Andrieux, Joris
Zhu, Wenmiao
He, Weimin
Vetrini, Francesco
Ward, Patricia A.
Cheung, Sau Wai
Bi, Weimin
Eng, Christine M.
Lupski, James R.
Yang, Yaping
Patel, Ankita
Lalani, Seema R.
Xia, Fan
Stankiewicz, Paweł
-
Funding
Funding for this research was provided by:
National Institutes of Health (U54HG006542, U01HG007709, NS058529)
Health Regional Agency from Poitou-Charentes (HUGODIMS, 2013, RC14_0107)
- License Information
-
More Information
Article History
Received: 11 October 2016
Accepted: 8 February 2017
First Online: 1 March 2017
Compliance with ethical standards
:
: JRL has stock ownership in 23andMe and Lasergen, is a paid consultant for Regeneron Pharmaceuticals, and is a co-inventor on multiple United States and European patents related to molecular diagnostics for inherited neuropathies, eye diseases, and bacterial genomic fingerprinting. The Department of Molecular and Human Genetics at Baylor College of Medicine derives revenue from the chromosomal microarray analysis and clinical exome sequencing offered by Baylor Genetics (ExternalRef removed).
